Skip to content
Constant Therapeutics

Constant Pharmaceuticals, LLC Announces Japanese Patent Issuance for TXA302 in Treatment of Stroke

TXA302 Shows Positive Activity in 3 models of stroke recovery

Boston, MA (March 7, 2018): Constant Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the treatment of stroke recovery, today announced that the Japanese Patent Office has issued a patent covering the use of TXA302 in the treatment of stroke. TXA302 is a proprietary analogue of the naturally occurring peptide Angiotensin (1-7).

“The issuance of this Japanese patent, combined with the already issued U.S. patent, strengthens our IP position around stroke and stroke recovery, where there remains significant, unmet medical need,” said Richard Franklin, President and Chief Executive Officer of Constant Pharmaceuticals LLC.

About 800,000 new cases of stroke occur annually in the U.S and over 200,000 new cases in Japan. Approximately 3.5 million stroke survivors in U.S. have ongoing mobility issues, and there are no currently approved medications for such impairments.

Previous Constant research has shown that TXA302 improves functional recovery across all endpoints in three different rat models of stroke recovery. Additionally, the functional recovery is correlated to an increase in blood flow and capillary density. TXA302 is an analogue of Angiotensin (1-7), which is part of an alternative pathway of the renin-angiotensin system. Constant research suggests that TXA302 achieves its effects on angiogenesis and plasticity in the brain by stimulating endothelial progenitor cells and oligodendrocyte progenitor cells, leading to increases in brain-derived neurotrophic factor and other factors. Seth Finkelstein, MD, PhD, Advisory Board Chairman of Constant Pharmaceuticals stated, “TXA302’s recent results using different models of stroke, where the peptide significantly improves functional recovery compared to control, is an exciting discovery. These results suggest that TXA302 might have potential use in the clinic.” Constant Pharmaceuticals expects to initiate a Phase 2 clinical trial in stroke recovery in early 2019.

About Constant Pharmaceuticals
Constant Pharmaceuticals LLC is a private biopharmaceutical company focused on the development of TXA127 and TXA302 for a variety of indications with an initial focus on stroke recovery. TXA127 is a pharmaceutical formulation of the naturally occurring peptide Angiotensin (1-7), and TXA302 is a proprietary analogue of TXA127. Constant Pharmaceuticals has broad IP protection for its peptides and is planning a Phase 2 study in stroke recovery. For more information on Constant Pharmaceuticals, please visit our website at

Elizabeth Wagner, Vice President
Tarix Orphan

Comments are closed.